We know vaccines reduce your risk of infection, but they aren't *perfect.* Then what fraction of transmission in the population is from the vaccinated? How might this change with new variants?

In the thread below, I share a mental model with worked examples. 1/11
First, some definitions. We are familiar with vaccine efficacy (VE) against disease. This was estimated from trials. But many studies have helped us estimate VE against all infection (aka VE_S). For mRNA vaccines against early strains, this has hovered around 80-90%. 2/11
Even if infected, are vaccine breakthroughs less likely to transmit? Due to lower viral load, shorter illness, location of replication (nose, lungs). This is VE against infectiousness (aka VE_I). A recent preprint estimated 50% (w/ high uncertainty). 3/11
medrxiv.org/content/10.110…
How often vaccinated individuals go on to transmit also depends upon:
- The level of exposure in the community
- The fraction of people vaccinated
- The reproduction number R_t
4/11
But in order to approximate the relative contribution of the two groups to transmission (the fraction A/(A+B)), we can simplify this down even further. If we assume exposure is similar for unvaccinated and vaccinated individuals, then several things cancel. 5/11
So, in this simplified model, the key is the % of the population vaccinated, plus the combination of the vaccine's effect to reduce infection and reduce infectiousness (sometimes called VE against transmission). 6/11
As a worked example, consider a vaccine that reduces infection by 80% and reduces infectiousness by 50%. If 50% of the population is vaccinated, about 9% of transmission is attributable to vaccinated individuals. 7/11
Remember this depends upon the fraction of the population vaccinated. Imagine the same vaccine but in a population with 80% vaccinated. Then the *relative* contribution of vaccinated individuals is higher, 29%, by virtue of there being more vaccinated. 8/11
[What's not captured in this simple relative contribution calculation is that, the more people who are vaccinated, the lower exposure will be for everyone! Instead I am looking just at a slice in time within a population, before the benefits accrue.] 9/11
We are still gathering evidence about the performance of these vaccines against newer variants. But we can see in this mental model how anything that erodes VE against infection or VE against infectiousness would increase the relative contribution from the vaccinated. 10/11
All the normal caveats that this is meant to be a simplified representation, but I hope it is helpful!
11/END
PS. I realize I use the word "simplified" in a few places, which I have been trying to move away from. ("It is trivial to show that..." is the worst.) I mean I made simplifying assumptions, but for those who aren't familiar with these equations, simple is the wrong word.

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Natalie E. Dean, PhD

Natalie E. Dean, PhD Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @nataliexdean

10 Jul
The discussion about COVID vaccine boosters is really many sub-discussions at once. The lack of a transparent decision framework makes it feel more confusing.

A thread below to start to break out the points…
Question 1) Are boosters safe and effective? This includes boosters of the original strain and based on new variants. This is addressed by new trials of these new combinations, including immune response data.
2) Do booster doses improve vaccine effectiveness? This depends upon seeing a loss of effectiveness, either from waning over time or against new variants. This can be detected in observational studies and inferred from immune response data.
Read 7 tweets
14 Jun
The return of vaccine Monday, but maybe one of the last placebo-controlled trial results. In their large US/Mexico trial, Novavax confirms the excellent result seen in an earlier UK trial. This includes efficacy against the circulating alpha (UK) variant.
The two dose protein subunit vaccine can be stored at refrigerated temperatures and is cheaper to produce. The company will apply for an EUA in the third quarter of 2021, as they need more time to validate the manufacturing process.
It’s unclear what the market in the US will look like in late 2020, but there is enormous global need. Efficacy against variants not widely circulating during the trial is also unclear. A Phase 2b trial in South Africa showed some drop, but with a wide confidence interval.
Read 4 tweets
7 Jun
A text from a colleague: "Ok how on earth has Twitter decided that we know VE against variants?" 🤔

Twitter does love certainty! But better to think about VE against variants in terms of likely ranges rather than precise estimates. So how do make these assessments? A thread.
Sometimes we have randomized clinical trial data, like J&J Ensemble trial in South Africa and South America. But often we are assembling data from disparate (and imperfect) sources...
nejm.org/doi/full/10.10…
Source 1: Data from immunoassays. We can look at neutralizing antibodies against different vaccines and assume this roughly correlates with VE. But we are still characterizing these relationships, and these assays do not capture cell-mediated immunity.
nature.com/articles/s4159…
Read 10 tweets
3 Jun
I hope people are aware of the enormous added value of HIV clinical trial networks. Groups who have been working on vaccine & treatment trials for decades leapt into action to work on COVID. OWS vaccine trials directly benefitted from the expertise of these groups. A big success!
There's a lot we can learn from this experience about:
- Leveraging existing networks
- Coordination between companies and researchers to standardize protocols across trials
- Using a centralized DSMB for oversight
- Pooling data, as planned for immune correlates analysis
A recent pub with more info:
"A single 11-member DSMB monitors all government-funded trials to ensure coordinated oversight, promote harmonized designs, and allow shared insights related to safety across trials."
@SteveJoffe et al.
academic.oup.com/jid/advance-ar…
Read 4 tweets
27 May
How will we know if we need COVID vaccine boosters?
If we observe that:
(1) Vaccine protection wanes over time.
(2) New immune escape variants emerge, resulting in a vaccine-strain mismatch.
These are distinct reasons. We can imagine how we would distinguish these in the data.
(1) Immunity wanes over time.
We would see that:
- Breakthrough cases occur most frequently in people who were vaccinated longest ago.
- These breakthrough cases include all types of strains.
(2) New immune escape variants emerge.
We would see that:
- Breakthrough cases are similarly common in people vaccinated recently and vaccinated longest ago.
- Breakthrough cases are disproportionately of the new variant type.
Read 4 tweets
24 May
In the US, we're rapidly building immunity thanks to highly effective vaccines. Cases have been quickly dropping. What might we expect in the coming months?

A few tweets on how I think about our patchwork of outbreaks... 1/6
Immunity will not be spread evenly throughout the population. While we track vaccination coverage at the national or state level, infectious disease dynamics are inherently local. Pockets of unvaccinated people who have not previously been infected will exist. 2/6
These pockets with lower immunity will remain at risk for outbreaks. While populations with high immunity may no longer be at risk for large outbreaks, movement between areas (and from across the globe) will lead to regular re-introductions and onward cases. 3/6
Read 6 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

:(